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According to Tolstoy, happy families were all alike, 
whereas unhappy families were each unhappy in their 
individual ways. So it is with the emergence of new 
virus infections. Each new virus epidemic brings mis-
ery to affected human populations, in unique ways. In 
the last 15 years, we have experienced the emergence 
and spread of Severe Acute Respiratory Syndrome 
(SARS), H5N1 and H7N9 influenza A viruses, pandemic 
influenza A(H1N1)pdm09, Middle Eastern Respiratory 
Syndrome (MERS) and Ebola virus disease, and most 
recently in 2015–16, Zika virus. The wider societal 
impact that such infectious disease events can cause 
has been amply demonstrated with Ebola virus in West 
Africa, which was responsible for over 11,000 deaths 
and has inhibited economic growth in this war-torn 
region of the world [1].
Each of the viruses mentioned above occupies a differ-
ent ecological niche, with diverse impact on the human 
population (magnitude of the epidemic, disease sever-
ity) as a result of transmission characteristics, host 
immune response and disease pathogenesis. Serious 
complications and deaths from Zika virus infection 
have not been common: most infections are asymp-
tomatic or very mild, although there is an association 
with neurological complications such as Guillain–Barré 
syndrome. The key issue, however, is the impact of 
infection on pregnancy.
For most emerging viruses, classical control measures 
of contact tracing and quarantine will eventually break 
chains of transmission between humans following 
zoonotic infection, when human-to-human transmis-
sion occurs and infectiousness is related to sympto-
matic illness. However, when infection is through a 
vector-borne route and sexual transmission can occur 
from a minimally symptomatic person, such as with 
Zika virus infection, additional population-based con-
trol measures must be undertaken. Vector control 
requires sustained and determined efforts to achieve 
a measurable impact and may involve a range of inter-
ventions at a personal level (e.g. avoidance, mosquito 
nets and insecticide) and at population level (e.g. 
breeding genetically resistant mosquitoes). Steering 
towards other rational interventions requires evidence 
from well-documented individual case studies.
Zika virus disease (ZVD) is a mosquito-borne infec-
tion caused by Zika virus, a member of the genus 
Flavivirus and family Flaviviridae. It was first isolated 
from a monkey in the Zika forest in Uganda in 1947. 
For those with symptoms, Zika virus generally causes 
a mild, short-lived (2–7 days) disease. Typical symp-
toms include: rash, itching/pruritus, low-grade fever, 
joint pain (with possible swelling mainly in the smaller 
joints of the hands and feet), conjunctivitis/red eyes, 
headache, muscle pain, lower back pain and eye pain 
– some of which were described in two of the case 
studies in this issue of Eurosurveillance [2,3]. However, 
the majority of people infected either do not have 
symptoms or have a very mild illness, and therefore 
the identification of symptom-free, but infectious indi-
viduals becomes much more problematic, particularly 
when coupled with consideration of sexual transmis-
sion of the virus, as described in the case report on 
sexual transmission in asymptomatic returning travel-
lers [4]. In Brazil, a country heavily and early affected 
by the current Zika virus epidemic, an upsurge of cases 
of ZVD in women has been noted, with the underly-
ing hypothesis that sexual transmission may be more 
important than hitherto recognised [5]. This may be 
consistent with modelling estimates that suggest that 
the Ro for transmission is lower than calculated for den-
gue, inferring that modes of infection other than Aedes 
aegypti bites might be involved [6]. The three articles 
in today’s Eurosurveillance add to the accumulating 
body of evidence of persistence of virus in seminal 
fluids and emphasise the sexual transmission of Zika 
virus, including sexual transmission between com-
pletely asymptomatic individuals [4].
While the exact relationship of detection of viral 
genome by reverse transcription-polymerase chain 
reaction (RT- PCR) and virus infectivity and transmissi-
bility from seminal fluid remains uncertain, the current 
European advice from the European Centre for Disease 
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Prevention and Control (ECDC) about prevention of sex-
ual transmission of viral infection through the use of 
safer sex with condoms for several months in return-
ing symptomatic and asymptomatic travellers from 
endemic areas [7] seems prudent and proportionate. 
The longest time for recovery of infectious virus from 
semen occurred at around 19–25 days post illness [8,9], 
the longest estimated time to sexual transmission fol-
lowing onset of illness is 32 to 41 days [10], whereas 
detection of viral genome to 60 days or more, previ-
ously noted in [8] is also noted in [2]. All of these esti-
mates are subject to some uncertainties, but strongly 
suggest viral persistence in an immunologically privi-
leged site. The kinetics of antibody response indicate 
that neutralising antibody will be present by this stage 
after illness onset. We should not be too surprised by 
this, following the demonstration of exactly this phe-
nomenon in survivors of Ebola virus disease [11]. Even 
though these are different groups of viruses with dif-
ferent pathogenesis, both have a viraemic phase with 
possible replication in vascular and reticuloendothelial 
tissue. As further data develop about duration of per-
sistence of viral material in the testes, pragmatic pub-
lic health advice about condom use, for a reasonable 
period beyond last known documented virus detection, 
may be a more rational and cost-effective approach 
than country-specific advice that returning travellers 
should routinely undergo laboratory testing.
There is scientific consensus that Zika virus is a cause 
of microcephaly and other congenital anomalies, also 
referred to as congenital Zika virus syndrome, the full 
definition for which continues to evolve as case-based 
information develops. The World Health Organization 
has thus started coordinating efforts to define con-
genital Zika virus syndrome and has issued an open 
invitation to all partners to join in this effort [12]. The 
combination of widespread asymptomatic infection, 
seminal fluid infectiousness, transmission from men 
to women and infection in early pregnancy, with a 
linkage to congenital anomaly, is an unfolding horror 
story, which we are ill-equipped to deal with. The cur-
rent scenario is a true global public health emergency, 
which requires an urgent raft of measures to minimise 
the impact. We should be under no illusions – it will 
take several years to find permanent solutions, such as 
vaccination.
The current response to Zika virus in mainland 
European countries is centred on limited numbers 
of cases of returning travellers. There will be a close 
watch in Europe in the coming summer season for any 
autochthonous transmission in areas where Ae. aegypti 
or Ae. albopictus is established [13], although the risks 
are considered to be low [7].
Disease control programmes start with awareness and 
accurate diagnosis. The symptoms of Zika virus infec-
tion can be similar to those of dengue, caused by a 
related flavivirus, or chikungunya, an alphavirus, which 
are often co-circulating in affected areas where Zika 
virus is present. Testing of symptomatic infections for 
individual case management is most needed in preg-
nancy. On the other hand, reliance on clinical diagno-
sis will not be sufficient to provide accurate estimates 
of disease burden in the affected countries and where 
laboratory capacity is limited. Laboratory testing of a 
proportion of all clinical cases is essential for feeding 
accurate information into predictive transmission mod-
elling. During the first five to seven days after onset of 
clinical illness during the acute viraemic phase, serum 
can be used for detection of viral genomic material by 
real-time RT-PCR. Body fluids such as urine or oral fluid 
may extend the window for genome detection during 
acute illness, and urine is already recommended for 
testing by some public health agencies [14]. These flu-
ids were useful in the limited case studies reported in 
Eurosurveillance [2,3]. As more data become available 
from cohort studies, information about the reliability 
of virus detection in different body compartments dur-
ing the acute phase of illness would be very welcome. 
Further partial genome sequencing may be helpful to 
confirm strain variation, and in any case will be impor-
tant to track the relationship between strain variation 
and clinical outcome.
Overall laboratory capacity and cost of testing will raise 
barriers to providing widespread diagnostic support in 
affected areas, but is less of an issue in Europe. There 
is an urgent need to develop low-cost, simple point-
of-care tests for viral antigen detection, as has been 
possible for dengue virus. It has taken many decades 
to realise the potential contribution of self-sampling, 
using non-invasive body fluids, to support disease 
control efforts. The detection of substantial amounts 
of Zika virus in urine and oral fluids suggests that 
detection of early infection could be attempted from 
these fluids. If dipsticks or similar simple devices can 
be developed for antibody detection, with sufficient 
sensitivity either for capillary blood finger prick testing 
and urine or for oral fluid sampling, the desirable goal 
of specific testing linked to self-sampling can provide 
some additional capacity within severely constrained 
health systems in affected countries.
Limited data from a small number of cases are cur-
rently available on the serological responses to Zika 
virus. There is antibody cross-reactivity with other 
flaviviruses, especially dengue virus and yellow fever 
virus or, less frequently, with West Nile virus. Serology 
focussing on the detection of viral E antigen, a key 
viral structural protein involved in virus receptor bind-
ing, is likely to demonstrate cross-reactivity between 
flaviviruses, as there is a high degree of conserva-
tion of the human immune response to this viral pro-
tein. Tests based around virus neutralisation need to 
be interpreted with caution and may not be useful as 
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first-line screening tests, although they may have a 
role in confirmation of antibody status. The applica-
tion of serological tests (ELISA or immunofluorescence) 
to detect specific IgM or IgG against Zika virus can be 
positive five to six days after the onset of symptoms. 
In line with classical antibody responses to infection, 
increased antibody titres are seen in paired samples, 
with an interval of about two weeks. The results of 
serological tests are much easier to determine in popu-
lations, such as returning European travellers, who 
mostly do not have a background of exposure to mul-
tiple co-circulating dengue subtypes or other flavivi-
ruses. Interpretation of serology in flavivirus-exposed 
populations will be much more challenging. There is an 
urgent necessity for Zika virus-specific IgG serological 
tests that can deliver a very high negative predictive 
value, and distinguish past infection with other flavi-
viruses, when applied in sero-epidemiological stud-
ies, as this will define the extent of susceptibility in 
the population, to inform wide-scale control measures. 
On the other hand, there is a need for serological tests 
that will deliver a high positive predictive value for 
Zika virus IgM detection following acute illness, where 
the narrow window for detection of the viral genome 
by PCR has been missed. It is particularly challenging 
to ensure that the correct individual diagnosis is made 
and pregnant women are not subjected to inappropri-
ate procedures for an infection that they do not have. 
Considerations of anamnestic response to diverse fla-
viviruses and original antigenic sin may be relevant in 
highly exposed populations and may give rise to posi-
tive serological test results, following acute illness, as 
a result of lack of specificity. The complexity of sero-
logical responses to Zika virus in light of previous mul-
tiple diverse flavivirus infections or vaccinations will 
require careful elaboration and comparison and pool-
ing of datasets internationally, as well as consideration 
of whether the risk of congenital anomaly is enhanced 
or reduced in the presence of pre-existing flavivirus 
antibody.
It may be some years before we have serology that is 
highly reliable at both the individual patient and popu-
lation level. There is a notable gap between the appli-
cation of serology to carefully studied individual cases, 
with confirmed genome detection and knowledge of 
dates of onset of illness, and the application of serol-
ogy to address the wider disease control questions, at 
scale, in diverse populations.
The development of serological tools for emerging 
infections inevitably lags behind the availability of 
accurate molecular diagnostic tools. The experience 
of SARS a decade ago, showed that even a year after 
the first serological tools were developed for detection 
of this infection, the number of laboratories that could 
reliably perform serology globally was severely limited 
[15]. The development of serological tools for MERS 
is also highly restricted. Urgent attention is required 
for the development and standardisation of serologi-
cal tools for Zika virus. It is entirely appropriate that 
international efforts are directed towards collabora-
tive serological studies, international standards and 
reagents for serology and study of the relationships 
between antibody responses to Zika virus and other 
flaviviruses, to define the protein epitopes involved 
in cross-reactivity, and address the potential for 
antibody-dependent enhancement between different 
groups of flaviviruses.
In summary, it will be crucial to provide support to 
affected countries to enable the development of robust 
serological tools, with the goal of ensuring safe preg-
nancies. Serological tests and algorithms for Zika 
virus-specific serological testing are in their infancy. 
Achieving reliability of testing will require sharing of 
data and reagents, a cooperative working approach 
to develop international standards and a hierarchy of 
serological algorithms. The current situation requires 
that we manage expectations and acknowledge uncer-
tainties to patients, physicians and politicians in this 
unhappy circumstance. Individual case reports, as 
published in Eurosurveillance today, have an important 
role in providing evidence to reduce uncertainties.
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